2021-2022 ISPE International Board of Directors
The Board is responsible for the governance and strategic direction of the Society. The following pharmaceutical industry leaders have been elected to positions on the 2020–2021 ISPE International Board of Directors:
To view the results of the 2022 Election and the 2022-2023 Board of Directors, visit the International Board Election Page.
2022 International Board of Directors Election Results
The ISPE International Board of Directors 2022 Election has concluded and the results are in. The leadership transition between the 2021 - 2022 Board and the 2022 - 2023 Board will take place during the 2022 ISPE Annual Meeting & Expo on Tuesday, 1 November.
ISPE is governed by an elected board of directors. The board is composed of fifteen elected members and the CEO & President, who serves as a non-voting ex-officio member. Directors are elected to a two-year term and can serve up to two terms consecutively. All terms commence at Annual Meeting. The officer positions are Chair, Vice Chair, Treasurer, Secretary, Past Chair and the President as a non-voting ex officio member. Terms for officers are one year and the Secretary is the first officer position in the typical officer succession. Each candidate for secretary is typically making a five-year commitment to serve in the roles of Secretary through Past Chair. During the September 2016 meeting of the ISPE International Board of Directors, two important modifications were incorporated into the ISPE Bylaws. The Board approved the appointment of a Director level position to the Board and the current Chair of the International Emerging Leaders Committee will be invited to board meetings as an ex-officio (non-voting) member as well. The main objective of these appointments was to ensure that ISPE has the appropriate diversity within the Board to execute business strategies as defined in our ISPE Strategic Plan. For additional information on the actions from the last Board meeting or access to governance actions visit the Governance Documents FAQs page.